<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="52124">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02124330</url>
  </required_header>
  <id_info>
    <org_study_id>RC 06-13</org_study_id>
    <secondary_id>RC 06/13</secondary_id>
    <nct_id>NCT02124330</nct_id>
  </id_info>
  <brief_title>Protein Sorbent Properties of Montmorillonite in Vitro and in Vivo Models</brief_title>
  <official_title>Protein Sorbent Properties of Montmorillonite in Vitro and in Vivo Models</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ronfani Luca</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Trieste</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IRCCS Burlo Garofolo</source>
  <oversight_info>
    <authority>Italy: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Montmorillonite (MONT) is a phyllosilicate layered mineral with unique physicochemical
      properties, such as swelling and cation exchange capability.

      The aim of this project is to study, in healthy volunteers, the in vivo ability of MONT to
      reduce protein intestinal uptake. Furthermore, the study analyzed in vitro the MONT ability
      of immobilizing proteins.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Montmorillonite (MONT) is a phyllosilicate layered mineral; chemically it is hydrated sodium
      calcium aluminium magnesium silicate hydroxide. Potassium, iron, and other cations are
      common substitutes and the exact ratio of cations varies with source.

      Due to its unique physicochemical properties, such as swelling and cation exchange
      capability, as well its mechanical and thermal stability, MONT can be efficiently used as
      matrix for immobilization of proteins with high molecular weight (e.g. Albumin) and proteins
      with low molecular weight (e.g.Aflatoxines). Therefore, MONT is used for therapeutic
      purposes, in pharmaceutical formulations and in food preparations. In vitro assays made in
      our laboratory, showed that MONT absorbs, in stable manner, alimentary proteins:
      beta-lactoglobulins, alfa lactoalbumines and the ratio MONT-protein (w/w) 1:3, 1:5, 1:15,
      results in the protein capture of 50, 27, 0 % of proteins respectively.

      The aim of this project is to study, in healthy volunteers, the in vivo ability of MONT to
      reduce protein intestinal uptake evaluated with the blood MONT- protein ratio. Furthermore,
      the study analyzed in vitro the MONT ability of immobilizing proteins at different ratio
      (w/w) 1:3, 1:5, 1:15.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Protein uptake evaluated with the blood MONT-protein ratio</measure>
    <time_frame>before administration and 30, 60, 90, 120 ,180 minutes after</time_frame>
    <safety_issue>No</safety_issue>
    <description>A solution of MONT and whey protein dissolved in 200 ml of water at the three different ratios will be administered. The control group will intake 15g of protein alone.
Blood samples will be centrifuged and analyzed by mass spectrometry (egilent HP5973 mass spectrometry).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Protein absorption by MONT in vitro</measure>
    <time_frame>at time of the trial</time_frame>
    <safety_issue>No</safety_issue>
    <description>MONT and protein (whey protein) at three different ratio w/w (1:3, 1:5, 1:15) will be dissolved in  acetate buffer 0.1M pH5 as well as a sample without MONT.
Samples will incubate at RT for 1, 10, 30, 60 minutes and then centrifugate at 13000g.
The surnatant will be analyzed by LOWRY method. Protein concentration will be expressed in mg/ml. The MONT ability of immobilization will be calculated respect to the protein control sample</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Urea Cycle Disorders, Inborn</condition>
  <condition>Other Metabolic Diseases</condition>
  <arm_group>
    <arm_group_label>montmorillonite 5 g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5g Montmorillonite + 15 g protein (ratio 1:3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Montmorillonite 3 g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3g Montmorillonite + 15 g protein (ratio 1:5)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Montmorillonite 1 g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1g Montmorillonite + 15 g protein (ratio 1:15)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>A control goup will intake 15 g of protein alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>montmorillonite 5 g</intervention_name>
    <description>5g montmorillonite + 15 g protein (ratio 1:3)</description>
    <arm_group_label>montmorillonite 5 g</arm_group_label>
    <other_name>montmorillonite 5 g</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>montmorillonite 3 g</intervention_name>
    <description>3g MONT+ 15 g protein (ratio 1:5)</description>
    <arm_group_label>Montmorillonite 3 g</arm_group_label>
    <other_name>montmorillonite 3 g</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Montmorillonite 1 g</intervention_name>
    <description>1g MONT+ 15 g protein (ratio 1:15)</description>
    <arm_group_label>Montmorillonite 1 g</arm_group_label>
    <other_name>Montmorillonite 1 g</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy volunteers (12M, 13 F, 25-30 years). Fasting from morning

        Exclusion Criteria:

          -  not defined
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tarcisio Not, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute for Maternal and Child Health IRCCS Burlo Garofolo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr. Tarcisio Not, MD</last_name>
    <phone>00390403785</phone>
    <phone_ext>472</phone_ext>
    <email>tarcisio.not@burlo.trieste.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ronfani Luca, MD</last_name>
    <phone>00390403785</phone>
    <phone_ext>401</phone_ext>
    <email>luca.ronfani@burlo.trieste.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institute for Maternal and Child Health IRCCS Burlo Garofolo</name>
      <address>
        <city>Trieste</city>
        <state>Friuli Venezia Giulia</state>
        <zip>34137</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tarcisio Not, MD</last_name>
      <phone>00390403785</phone>
      <phone_ext>472</phone_ext>
      <email>tacisio.not@burlo.trieste.it</email>
    </contact>
    <investigator>
      <last_name>Tarcisio Not, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 24, 2014</lastchanged_date>
  <firstreceived_date>October 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Burlo Garofolo</investigator_affiliation>
    <investigator_full_name>Ronfani Luca</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>Montmorillonite, proteic diet, in vitro and in vivo models</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Urea Cycle Disorders, Inborn</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bentonite</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
